Abe et al. [30] recently reported a reduction of HbA1c levels in a cohort of osteoporotic patients with T2DM after one year of Dmab treatment, strengthening the hypothesis that the impact of RANKL blockade may be more relevant in presence of overt abnormalities of glucose homeostasis. The gene discussed is TNFSF11; the disease is type 2 diabetes mellitus.